Press release

Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet

CHENGDU, China, May 30, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”, 6990.HK) announced today that the results of…

Read More »

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC   SEZ6 expression is positively correlated with DLL3…

Read More »

Real Estate Expert Justus Smith of Keystone Explains Where Real Estate Commission Dollars Go for HelloNation

KEYSTONE, Fla., May 30, 2026 /PRNewswire/ — When selling a home, where do real estate commission dollars actually go? A HelloNation…

Read More »

MakerWorld’s First User-Initiated Charity Contest Names Winners, Bringing Global Creators’ Goodwill Directly to Cancer Wards

AUGSBURG, Germany, May 30, 2026 /PRNewswire/ — MakerWorld’s first user-initiated charity design contest has completed: winners have now been selected…

Read More »

The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet

CHENGDU, China, May 29, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”, 6990.HK) announced today that at the…

Read More »

Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO

CHENGDU, China, May 29, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”, 6990.HK) announced that at the 2026…

Read More »

Plaza Home Mortgage Announces Security Incident

COSTA MESA, Calif., May 29, 2026 /PRNewswire/ — The following statement is being issued by Simpluris, Inc., as the notice administer…

Read More »